Jonathan E. Rosenberg, MD
Chief, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz Chair
Bladder Cancer; Ureter Cancer; Urachal Cancer; Renal Pelvis Cancer; Transitional Cell (Urothelial) Carcinoma; Urethral Cancer
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Rosenberg accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Formerly known as Health Plus Amerigroup, Empire Blue Cross Blue Shield Health Plus is an in-network provider with Memorial Sloan Kettering. You will need a one-time referral from your primary care doctor.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with Medicaid NY Empire Blue Cross Blue Shield HealthPlus (formerly known as Amerigroup). You will need a one-time referral from your primary care doctor.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, Harvard Medical School
Internal Medicine - NewYork-Presbyterian/Weill Cornell Medical Center
Medical Oncology - University of California Medical Center
I am a medical oncologist who cares for people with genitourinary cancers. I have extensive experience treating urothelial cancers, which start in the bladder, ureters, renal pelvis, or urethra.
My interest in cancer was sparked as I watched my grandfather live with and ultimately pass away from prostate cancer. I witnessed firsthand the limited treatment options available for this disease in the 1980s. His experience inspired me to pursue a career in cancer research and treatment to improve outcomes for people with genitourinary cancers.
I see more than 1,000 patients every year. My goal is to tailor treatment according to each person’s needs and circumstances. I work as part of a team of cancer experts. We focus on all aspects of oncology to provide complete care for people with these diseases.
A urothelial cancer diagnosis can lead to understandable fear and confusion. When patients see me for the first time, they express concern about the extent of their illness, the available treatment options, and their prognosis. Educating patients to help them make informed decisions about their care is an important part of my job. I hope that people leave a visit with me with a better understanding of their condition and treatment options.
My research centers on developing treatment approaches and improving care for people with bladder cancer. My work includes understanding the genetic changes that lead to this cancer’s aggressiveness. I use those insights to develop new therapies. I also have a research interest in identifying useful predictive biomarkers. These tests help doctors pick treatments that may be more likely to work for a particular individual. I lead or participate in several studies that are testing these biomarkers.
I study new treatments that target cellular processes that fuel the growth and progression of bladder cancer and test new ways to harness the immune system to fight urothelial cancer. I lead multiple clinical trials evaluating targeted therapy, chemotherapy, and immunotherapy, either alone or in various combinations. I have been a leader in the development of immunotherapy for people with urothelial cancer that has spread and led the clinical trial that resulted in the first new drug approval by the US Food and Drug Administration for urothelial cancer in more than 20 years. I was also principal investigator of another trial that led to the FDA’s Breakthrough Therapy Designation for a new drug for this disease.
I became Chief of MSK’s Genitourinary Oncology Service in 2018. Before that, I was the Section Head for non-prostate genitourinary cancers at MSK. Prior to arriving at MSK in 2012, I was Clinical Director of the Genitourinary Oncology Center and Director of the Bladder Cancer Center at the Dana-Farber/Brigham and Women’s Cancer Center of Harvard Medical School.
I serve on several national committees dedicated to improving treatment for people with genitourinary cancers. I travel widely to speak about bladder cancer and immunotherapy, and I have presented my research at many national and international meetings.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Investigated by Dr. Rosenberg
- A Phase I Study of ASG-22CE in Patients with Metastatic Urothelial Cancers Containing Nectin-4
- A Phase IB Study of Enfortumab Vedotin plus Immunotherapy for Patients with Locally Advanced or Metastatic Urothelial Cancer
- A Phase IB/II Study of Rogaratinib and Atezolizumab as Initial Treatment in Patients with FGFR-Positive Advanced or Metastatic Urothelial Carcinoma Who Cannot Receive Cisplatin
- A Phase II Study of Durvalumab Immunotherapy plus Olaparib as Initial Treatment of Patients with Metastatic Urothelial Cancer
- A Phase II Study of Enfortumab Vedotin (ASG-22CE) in Patients with Advanced Urothelial Cancers Previously Treated with Immunotherapy
- Clinical Trials Co-Investigated by Dr. Rosenberg
- A Phase II Study of Atezolizumab Immunotherapy plus Bevacizumab for Patients with Metastatic Urothelial Cancer Who Cannot Have Cisplatin-Based Chemotherapy
- A Phase II Study of Pembrolizumab Immunotherapy, Gemcitabine, and Radiation Therapy for Patients with Bladder Cancer
- A Phase II Study of Sitravatinib plus Nivolumab Immunotherapy in Patients with Advanced or Metastatic Urothelial Cancer
- A Phase II Study of Two Dosing Schedules of Atezolizumab Immunotherapy plus Chemotherapy for Metastatic Bladder Cancer
- A Phase III Study Comparing Pembrolizumab Immunotherapy with Observation after Surgery for Localized Muscle-Invasive Bladder Cancer
- A Pilot Study Assessing Immunotherapy with Nivolumab Alone or with Ipilimumab Before Surgery for Patients with Muscle-invasive Bladder Cancer Who Cannot Have Cisplatin-Based Chemotherapy
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Rosenberg’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jonathan E. Rosenberg discloses the following relationships and financial interests:
Janssen Pharmaceuticals, Inc.
Provision of Services
Merck & Co Inc.
Provision of Services
Provision of Services
Provision of Services
Research to Practice
Provision of Services
Provision of Services (uncompensated)
Provision of Services
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.